ZLDAF (Zelira Therapeutics) Cash Flow for Dividends: $0.00 Mil (TTM As of Jun. 2025)


ZLDAF Zelira Therapeutics Ltd ZLDAF
10 GF Score
Price $0.35
GF Value $0.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Cash Flow for Dividends?

Zelira Therapeutics ZLDAF 10 Cash Flow for Dividends is $0.00 Mil as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Zelira Therapeutics's cash flow for dividends for the six months ended in Jun. 2025 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Zelira Therapeutics Cash Flow for Dividends Related Terms

Zelira Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Cash Flow for Dividends Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZLDAF
10GF Score
Zelira Therapeutics Ltd ZLDAF
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $0.00 Mil mean?
Zelira Therapeutics (ZLDAF) has a Cash Flow for Dividends of $0.00 Mil as of Jun. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Cash Flow for Dividends too high?
Zelira Therapeutics' current Cash Flow for Dividends is $0.00 Mil. Overall, Zelira Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Cash Flow for Dividends compare to MTNB and SXTP?
Zelira Therapeutics' Cash Flow for Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Zelira Therapeutics and its competitors. Zelira Therapeutics's current Cash Flow for Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current Cash Flow for Dividends is $0.00 Mil. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Cash Flow for Dividends is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Cash Flow for Dividends: $0.00 Mil
  • GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
  • GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score

Get the complete analysis for ZLDAF

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.08
GF Value